Neeraj Gupta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5029199/publications.pdf

Version: 2024-02-01

67	3,069	236925	161849
papers	citations	25 h-index	54 g-index

69	69	69	3261
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Brigatinib versus Crizotinib in ALK-Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2027-2039.	27.0	691
2	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncology, The, 2014, 15, 1503-1512.	10.7	233
3	Brigatinib Versus Crizotinib in Advanced ALK Inhibitorâ€“Naive ALK-Positive Nonâ€“Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Journal of Clinical Oncology, 2020, 38, 3592-3603.	1.6	224
4	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood, 2014, 124, 1038-1046.	1.4	192
5	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
6	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood, 2014, 124, 1047-1055.	1.4	185
7	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, 2017, 130, 597-605.	1.4	108
8	Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies. Journal of Clinical Oncology, 2009, 27, 4718-4726.	1.6	87
9	Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1418-1425.	1.1	59
10	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. Journal of Hematology and Oncology, 2017, 10, 137.	17.0	56
11	Switching from body surface areaâ€based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. British Journal of Clinical Pharmacology, 2015, 79, 789-800.	2.4	50
12	A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or endâ€stage renal disease requiring haemodialysis. British Journal of Haematology, 2016, 174, 748-759.	2.5	48
13	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. British Journal of Haematology, 2017, 178, 571-582.	2.5	45
14	Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clinical Pharmacokinetics, 2019, 58, 431-449.	3.5	45
15	Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. Blood Cancer Journal, 2014, 4, e251-e251.	6.2	43
16	Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. Clinical Pharmacokinetics, 2017, 56, 1355-1368.	3.5	40
17	Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. British Journal of Clinical Pharmacology, 2016, 82, 728-738.	2.4	38
18	Pharmacokinetics and safety of ixazomib plus lenalidomideâ€“dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. Journal of Hematology and Oncology, 2015, 8, 103.	17.0	37

#	Article	IF	Citations
19	Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011â€“2017: Lessons Learned for Anticancer Drug Development. Clinical and Translational Science, 2018, 11, 123-146.	3.1	36
20	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Investigational New Drugs, 2015, 33, 652-663.	2.6	35
21	The Effect of a Highâ€Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. Journal of Clinical Pharmacology, 2016, 56, 1288-1295.	2.0	34
22	Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer, 2011, 47, 2706-2714.	2.8	33
23	Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drugâ€Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis. Journal of Clinical Pharmacology, 2018, 58, 180-192.	2.0	33
24	Twiceâ€weekly ixazomib in combination with lenalidomideâ€dexamethasone in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2018, 182, 231-244.	2.5	30
25	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncology, 2015, 11, 1153-1168.	2.4	25
26	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. European Journal of Cancer, 2019, 106, 89-98.	2.8	25
27	Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use. Clinical Pharmacology and Therapeutics, 2018, 103, 378-383.	4.7	23
28	Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. Journal of Thoracic Oncology, 2020, 15, 1190-1199.	1.1	23
29	Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients. Cancer Chemotherapy and Pharmacology, 2015, 76, 507-516.	2.3	21
30	Exposureâ€“safetyâ€“efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study. Investigational New Drugs, 2016, 34, 338-346.	2.6	19
31	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Targeted Oncology, 2017, 12, 643-654.	3.6	19
32	New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib. Journal of Blood Medicine, 2017, Volume 8, 107-121.	1.7	19
33	The Effect of a Highâ€Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2019, 8, 734-741.	1.6	19
34	Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2020, 9, 214-223.	1.6	19
35	A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1518-1526.	3.5	18
36	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. Blood, 2013, 122, 535-535.	1.4	18

#	Article	IF	Citations
37	Phase 2 study of allâ€oral ixazomib, cyclophosphamide and lowâ€dose dexamethasone for relapsed/refractory multiple myeloma. British Journal of Haematology, 2019, 184, 536-546.	2.5	16
38	Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. Journal of Clinical Pharmacology, 2017, 57, 1183-1193.	2.0	15
39	A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 407-415.	2.6	15
40	Brigatinib Dose Rationale in Anaplastic Lymphoma Kinaseâ€"Positive Nonâ€Small Cell Lung Cancer: Exposureâ€"Response Analyses of Pivotal ALTA Study. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 718-730.	2.5	15
41	Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. Clinical Pharmacokinetics, 2021, 60, 235-247.	3.5	15
42	Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAKâ€788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2021, 10, 1044-1053.	1.6	13
43	Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3077-3077.	1.6	13
44	A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). Blood, 2012, 120, 332-332.	1.4	12
45	MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study. Blood, 2012, 120, 731-731.	1.4	12
46	Singleâ€Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAKâ€788) in Healthy Volunteers: Lowâ€Fat Meal Effect and Relative Bioavailability of 2 Capsule Products. Clinical Pharmacology in Drug Development, 2021, 10, 1028-1043.	1.6	11
47	Transforming Translation Through Quantitative Pharmacology for Highâ€Impact Decision Making in Drug Discovery and Development. Clinical Pharmacology and Therapeutics, 2020, 107, 1285-1289.	4.7	10
48	Modelâ€Based Metaâ€Analysis for Multiple Myeloma: A Quantitative Drugâ€Independent Framework for Efficient Decisions in Oncology Drug Development. Clinical and Translational Science, 2018, 11, 218-225.	3.1	9
49	Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2016, 128, 3327-3327.	1.4	8
50	Modelâ€Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. Clinical Pharmacology and Therapeutics, 2019, 105, 376-387.	4.7	7
51	Effect of severe renal impairment on the pharmacokinetics of brigatinib. Investigational New Drugs, 2021, 39, 1306-1314.	2.6	7
52	A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. Targeted Oncology, 2022, 17, 15-24.	3.6	7
53	Population pharmacokinetic and exposureâ€response analyses from ALTAâ€1L: Modelâ€based analyses supporting the brigatinib dose in ALKâ€positive NSCLC. Clinical and Translational Science, 2022, 15, 1143-1154.	3.1	7
54	Asiaâ€Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo. Clinical Pharmacology and Therapeutics, 2023, 113, 298-309.	4.7	7

#	Article	IF	Citations
55	Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposureâ€“Response Analyses of a Pivotal Phase I/II Study. Clinical Pharmacology and Therapeutics, 2022, 112, 327-334.	4.7	7
56	Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces. Cancer Chemotherapy and Pharmacology, 2018, 82, 803-814.	2.3	6
57	Flat-Dosing Versus BSA-Based Dosing for MLN9708, An Investigational Proteasome Inhibitor: Population Pharmacokinetic (PK) Analysis of Pooled Data From 4 Phase-1 Studies. Blood, 2011, 118, 1433-1433.	1.4	6
58	Population pharmacokinetics of mobocertinib in healthy volunteers and patients with nonâ€“small cell lung cancer. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 731-744.	2.5	6
59	A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. Journal of Clinical Pharmacology, 2018, 58, 114-121.	2.0	5
60	Clinical Pharmacokinetics of Intravenous and Oral MLN9708, An Investigational Proteasome Inhibitor: An Analysis of Data From Four Phase 1 Monotherapy Studies. Blood, 2010, 116, 1813-1813.	1.4	5
61	Population Pharmacokinetics of TAKâ€931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Pharmacology, 2021, , .	2.0	4
62	Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINEâ€MM1 study in multiple myeloma patients. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1085-1099.	2.5	4
63	Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma. Blood, 2012, 120, 3646-3646.	1.4	3
64	A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma.. Journal of Clinical Oncology, 2013, 31, 2555-2555.	1.6	2
65	Assessment of Effects of Investigational TAKâ€931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors. Clinical Pharmacology in Drug Development, 2022, , .	1.6	2
66	The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685). Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S337-S338.	0.4	1
67	Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinaseâ€positive nonâ€small cell lung cancer. British Journal of Clinical Pharmacology, 2022, 88, 3922-3923.	2.4	1